Pangaea Oncology, S.A. (BME: PANG)

Market Cap	53.66M
Revenue (ttm)	9.95M
Net Income (ttm)	-4.66M
Shares Out	30.14M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	767
Open	1.790
Previous Close	1.780
Day's Range	1.790 - 1.790
52-Week Range	1.470 - 1.790
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnost...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 149
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2023, NBI's revenue was 53.47 million, an increase of 14.07% compared to the previous year's 46.87 million. Earnings were 1.14 million, a decrease of -11.79%.